Supra-Annular Versus Intra-Annular Self-Expanding Valves in Small Aortic Annulus: A Propensity Score-Matched Study DOI Creative Commons
Michel Pompeu Sá, Danial Ahmad, Yisi Wang

et al.

Structural Heart, Journal Year: 2024, Volume and Issue: 9(1), P. 100334 - 100334

Published: July 8, 2024

Language: Английский

Evolut PRO and SAPIEN ULTRA Performance in Small Aortic Annuli DOI Creative Commons
Andrea Scotti, Matteo Sturla, Giuliano Costa

et al.

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Journal Year: 2024, Volume and Issue: 17(5), P. 681 - 692

Published: March 1, 2024

Language: Английский

Citations

13
Incidence, Predictors, and Prognostic Impact of New Permanent Pacemaker Implantation After TAVR With Self-Expanding Valves DOI Creative Commons
Matteo Pagnesi, Won‐Keun Kim, Sara Baggio

et al.

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Journal Year: 2023, Volume and Issue: 16(16), P. 2004 - 2017

Published: July 19, 2023

Language: Английский

Citations

22
Mediators of Improvement in TAVR Outcomes Over Time: Insights From the STS-ACC TVT Registry DOI Creative Commons
Suzanne V. Arnold, Pratik Manandhar, Sreekanth Vemulapalli

et al.

Circulation Cardiovascular Interventions, Journal Year: 2023, Volume and Issue: 16(7)

Published: June 26, 2023

Over the past decade, there has been substantial improvement in outcomes after transcatheter aortic valve replacement. Many patient and procedural factors have also changed over that time, making it challenging to untangle drivers of those improvements.

Language: Английский

Citations

17
Predictors, clinical impact, and management strategies for conduction abnormalities after transcatheter aortic valve replacement: an updated review DOI Creative Commons

Qingyun Yu,

Qingan Fu,

Yunlei Xia

et al.

Frontiers in Cardiovascular Medicine, Journal Year: 2024, Volume and Issue: 11

Published: April 8, 2024

Transcatheter aortic valve replacement (TAVR) has increasingly become a safe, feasible, and widely accepted alternative surgical treatment for patients with severe symptomatic stenosis. However, the incidence of conduction abnormalities associated TAVR, including left bundle branch block (LBBB) high-degree atrioventricular (HAVB), remains high is often correlated risk factors such as severity valvular calcification, preexisting conditions in patients, procedural factors. The existing research results on impact post-TAVR permanent pacemaker (PPM) requirements prognosis, all-cause mortality rehospitalization, remain contradictory, varied management strategies system diseases across different institutions. This review integrates latest field, offering comprehensive discussion mechanisms, factors, consequences, abnormalities. study provides insights into optimizing patient prognosis explores potential novel strategies, pacing, to minimize adverse clinical outcomes.

Language: Английский

Citations

5
Use and performance of the evolut FX transcatheter aortic valve system DOI
Tanvir Bajwa, Guilherme F. Attizzani,

Hemal Gada

et al.

Cardiovascular revascularization medicine, Journal Year: 2024, Volume and Issue: 67, P. 1 - 7

Published: April 7, 2024

Language: Английский

Citations

4
Safety and effectiveness of self-expanding TAVR in Japanese Dialysis patients with severe aortic stenosis: 1-year outcomes DOI
Koki Shishido,

Futoshi Yamanaka,

Noriaki Moriyama

et al.

Journal of Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Aortic Valve Intervention in Patients with Aortic Stenosis and Small Annulus DOI Creative Commons
Ahmed Abdalwahab, Muntaser Omari, Mohammad Alkhalil

et al.

Reviews in Cardiovascular Medicine, Journal Year: 2025, Volume and Issue: 26(3)

Published: March 24, 2025

Over the last two decades, management of aortic stenosis has undergone significant transformation due to developments in surgical techniques and introduction transcatheter valve implantation (TAVI). These transformations have enabled improved patient selection treatments be tailored based on individual clinical anatomical characteristics. Both options resulted reduced mortality enhanced quality life for patients with stenosis. Nonetheless, treating small annulus remains challenging despite advances current technology. The insertion a prosthetic valve, leading mismatch, been associated heart failure hospitalization, early structural degeneration, long-term mortality. Although root enlargement was historically employed address this issue, stentless sutureless valves supra-annular position and, more recently, TAVI emerged as alternative severe This review will provide an overview prevalence characteristics annulus. Additionally, we discuss treatment options, including surgery TAVI, used mitigate procedural adverse outcomes group.

Language: Английский

Citations

0
Transcatheter Aortic Valve Replacement with a Fully Retrievable Self-Expanding Dry-Tissue Valve: First-in-Man Study DOI
Zhen‐Gang Zhao, Yong Peng, Fei Chen

et al.

The American Journal of Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Trends in Transcatheter Aortic Valve Replacement Outcomes DOI
Suzanne V. Arnold, Pratik Manandhar, Sreekanth Vemulapalli

et al.

JAMA Cardiology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 16, 2024

Importance Although transcatheter aortic valve replacement (TAVR) outcomes in the US have improved substantially since 2011, it is unknown whether these trends continued 2019. Objective To examine changes risk-adjusted TAVR from 2019 to 2022 and any noteworthy over time. Design, Setting, Participants This cohort study examined data patients with severe stenosis treated at 786 hospitals between January 1, 2019, March 31, 2022, included Society of Thoracic Surgeons (STS)/American College Cardiology (ACC) Transcatheter Valve Therapies (TVT) Registry. Exposure Patients who underwent TAVR. Main Outcomes Measures The primary outcome was 30-day mortality, secondary were in-hospital mortality composite adverse events. understand factors explaining trends, a series logistic regression models constructed for each outcome, time as explanatory variable. After adjusting changing patent characteristics procedural factors, exploratory analyses performed extent which findings could be explained by several plausible hypotheses. Results study’s analytic total 210 495 patients. Median (IQR) patient age 79 (73-85) years, 91 313 (43.4%) female. STS predicted risk (PROM) 3.3% (2.0%-5.3%). There no significant unadjusted quarter 1 (2.4%) end (2.2%) ( P trend = .10), an odds ratio (OR) 0.98 per year (95% CI, 0.94-1.01). characteristics, OR increased 1.05 1.02-1.08), further after 1.09 1.05-1.13). In analyses, there meaningful adjusted death excluding sites that entered STS/ACC TVT Registry or later (OR, 1.09; 95% 1.05-1.13), low-volume 1.06-1.13), low-risk 1.11; 1.07-1.15), bicuspid deaths 1.08; 1.03-1.14), experienced major vascular complication 1.05-1.12). Conclusions Relevance this observational performing national analysis TAVR, found modestly 2022. However, site-level, patient-related, process-related identified explain findings. absolute increase during period relatively small, warrant surveillance.

Language: Английский

Citations

3
Early experience with the Evolut FX self-expanding valve vs. Evolut PRO+ for patients with aortic stenosis undergoing TAVR DOI
Ilan Merdler, Brian C. Case, Sukhdeep Bhogal

et al.

Cardiovascular revascularization medicine, Journal Year: 2023, Volume and Issue: 56, P. 1 - 6

Published: June 5, 2023

Language: Английский

Citations

9